HIV合并心衰患者的NT-proBNP特征与预后
该研究基于学术中心一年内因心衰住院的患者注册数据,比较HIV感染者与未感染对照组之间的NT-proBNP浓度及其变化。结果显示,HIV感染者入院和出院NT-proBNP更高、下降幅度更小,且高NT-proBNP与心血管死亡风险增加相关,病毒载量和CD4计数与NT-proBNP水平相关。
要点
- HIV合并心衰者入院和出院NT-proBNP均更高,住院期间降幅更小。
- 高病毒载量、低CD4计数与更高NT-proBNP水平相关。
- HIV合并心衰者入院NT-proBNP越高,心血管死亡风险越高。
核心结论
- HIV合并心衰患者入院和出院NT-proBNP水平更高,且住院期间NT-proBNP变化幅度更小。
- 在HIV感染者中,病毒载量和CD4计数与NT-proBNP浓度相关。
- HIV合并心衰患者随访期间,较高的NT-proBNP水平与心血管死亡相关。
研究设计与样本
- 研究为注册研究,纳入某学术中心一个日历年内因心衰住院的患者。
- 共纳入2578例心衰患者,其中434例为HIV感染者。
主要发现
- HIV感染者入院NT-proBNP为5546(IQR 3257-8792)pg/ml,对照组为3822(IQR 2413-7784)pg/ml,P < .001。
- HIV感染者出院NT-proBNP为3372(IQR 1553-5452)pg/ml,对照组为1922(IQR 1045-4652)pg/ml,P < .001。
- HIV感染者入院至出院NT-proBNP变化为32%,对照组为48%,P = .007。
- 多因素分析中,可卡因使用、较低LVEF、较高NYHA分级、较高病毒载量和较低CD4计数与较高NT-proBNP浓度相关。
- HIV感染者中,入院NT-proBNP三分位组心血管死亡率分别为11.5%、20%和44%,P < .001;NT-proBNP每翻倍,死亡风险增加19%。
关键数值与推荐
- HIV感染者中90%接受抗逆转录病毒治疗,62%达到病毒学抑制。
- 按LVEF分层后,NT-proBNP差异结果相似。
- 未感染HIV患者中,NT-proBNP每翻倍与27%的死亡风险增加相关,该差异在低病毒载量和高CD4计数的HIV感染者中减弱。
临床怎么用
- 对HIV合并心衰患者应关注NT-proBNP水平,入院和出院NT-proBNP均较高且降幅较小。
- 评估NT-proBNP时应结合病毒载量和CD4计数,高病毒载量或低CD4计数者NT-proBNP可能更高。
- HIV合并心衰患者入院NT-proBNP升高提示心血管死亡风险增加,可用于风险分层。
局限性
- 研究为单中心注册研究,结果外推需谨慎。
- 原文未报告研究的具体年份、随访时长及失访情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among persons living with human immunodeficiency virus (PHIV), incident heart failure (HF) rates are increased and outcomes are worse; however, the role of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations among PHIV with HF has not been characterized. METHODS: Patients were derived from a registry of those hospitalized with HF at an academic center in a calender year. We compared the NT-proBNP concentrations and the changes in NT-proBNP levels between PHIV with HF and uninfected controls with HF. RESULTS: Among 2578 patients with HF, there were 434 PHIV; 90% were prescribed antiretroviral therapy and 62% were virally suppressed. As compared to controls, PHIV had higher admission (3822 [IQR, 2413-7784] pg/ml vs 5546 [IQR, 3257-8792] pg/ml, respectively; P < .001), higher discharge (1922 [IQR, 1045-4652] pg/ml vs 3372 [IQR, 1553-5452] pg/ml, respectively; P < .001), and lower admission-to-discharge changes in NT-proBNP levels (32 vs 48%, respectively; P = .007). Similar findings were noted after stratifying based on left ventricular ejection fraction (LVEF). In a multivariate analysis, cocaine use, a lower LVEF, a higher NYHA class, a higher viral load (VL), and a lower CD4 count were associated with higher NT-proBNP concentrations. In follow-up, among PHIV, a higher admission NT-proBNP concentration was associated with increased cardiovascular mortality (first tertile, 11.5; second tertile, 20; third tertile, 44%; P < .001). Among PHIV, each doubling of NT-proBNP was associated with a 19% increased risk of death. However, among patients living without HIV, each doubling was associated with a 27% increased risk; this difference was attenuated among PHIV with lower VLs and higher CD4 counts. CONCLUSIONS: PHIV with HF had higher admission and discharge NT-proBNP levels, and less change in NT-proBNP concentrations. Among PHIV, VLs and CD4 counts were associated with NT-proBNP concentrations; in follow-up, higher NT-proBNP levels among PHIV were associated with cardiovascular mortality.
引用
- Alvi RM, Zanni MV, Neilan AM, et al. Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure. Clin Infect Dis. 2020. PMID: 31740919. doi:10.1093/cid/ciz958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。